Research Topics
Species | Gene MorseSummaryAffiliation: University at Buffalo Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individualsGene D Morse
Adult ACTG Pharmacology Support Laboratory, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260, USA
Antimicrob Agents Chemother 49:3373-81. 2005..7 to 1.0; P = 0.042). African-American non-Hispanics had higher day 14 efavirenz AUCs than white non-Hispanics. We conclude that EFV lowered APV AUCs, but nelfinavir, indinavir, or ritonavir compensated for EFV induction...- Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan AfricaFatai A Fehintola
Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Nigeria
Curr Drug Metab 12:51-6. 2011.... 
Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapyGene D Morse
Department of Pharmacy Practice, University at Buffalo, State University of New York, Amherst 14260, USA
Lancet Infect Dis 6:215-25. 2006..Current investigation is focused on examining the predictive value of this approach for clinical monitoring...- Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and applicationKim Keil
Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
Ther Drug Monit 29:103-9. 2007..During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM... - Buprenorphine assay and plasma concentration monitoring in HIV-infected substance usersRobin DiFrancesco
Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
J Pharm Biomed Anal 44:188-95. 2007..Use of this combined BUP and ARV plasma concentration monitoring approach for a representative patient receiving BUP, atazanavir and efavirenz demonstrated its clinical application... - Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoringJudianne Slish
Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
Ther Drug Monit 29:560-5. 2007..Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users... - Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavirNiamh Higgins
Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
Am J Addict 16:488-94. 2007..These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects... - Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patientsMark J Shelton
Laboratory for Antiviral Research, Department of Pharmacy Practice, University at Buffalo, New York, USA
Antimicrob Agents Chemother 47:1694-9. 2003..h, and a C(min) of 9.1 +/- 7.5 micro M. Therefore, delavirdine increases systemic exposure to ritonavir by 50 to 80% when the drugs are coadministered... - Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasmaKim Keil
Department of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14260, USA
Ther Drug Monit 25:340-6. 2003..1 to 0.2 microg/mL with an interday variation in CV ranging from 3.5% to 10.4%. The method is being applied to a TDM program that is currently being implemented in the authors' laboratory... - Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsRobert Dicenzo
University at Buffalo, Buffalo, New York, USA
Antimicrob Agents Chemother 47:1929-35. 2003..Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h... - A dose-ranging study of a methylphenidate transdermal system in children with ADHDWilliam E Pelham
State University of New York at Buffalo, NY, USA
J Am Acad Child Adolesc Psychiatry 44:522-9. 2005..Medication (placebo, 0.45, 0.9, and 1.8 mg/h) was crossed with application time (6 a.m., 7 a.m.) to evaluate MTS efficacy and influence of exposure time on morning effects... - Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIVQing Ma
University at Buffalo, Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, NY, USA
Pharmacogenomics 8:227-35. 2007..We examined MDR1 single nucleotide polymorphisms in a cohort of patients in whom therapeutic drug monitoring is ongoing through a research protocol... - Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode arrayKim Keil
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
Ther Drug Monit 28:512-6. 2006..390 microg/mL with an interday variation in control value ranging from 2.9 to 4.6%. The method is being used in a clinical therapeutic drug monitoring program that is ongoing in our laboratory... - Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitorsQing Ma
University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA
Expert Opin Drug Metab Toxicol 1:473-85. 2005..This review provides an updated summary of pharmacokinetic interactions with NNRTIs... - Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith
Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
Antimicrob Agents Chemother 49:3558-61. 2005..There were no significant differences in efavirenz pharmacokinetics... - Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individualsPatrick F Smith
Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
Clin Pharmacokinet 44:99-109. 2005..Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies... - Advances in pharmacogenomics of antiretrovirals: an updateQing Ma
Pharmacotherapy Research Center, University at Buffalo, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY 14260, USA
Pharmacogenomics 8:1169-78. 2007..Future directions for research and the application of this technology to the clinical practice of individualizing treatment for HIV management are discussed... - Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteersQing Ma
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14260, USA
Biopharm Drug Dispos 29:91-101. 2008..In conclusion, concomitant administration of dual PIs is unlikely to have any clinically significant effect on the pharmacokinetics of CYP2B6 substrates in general or oral efavirenz specifically... - Determination of protease inhibitors using liquid chromatography-tandem mass spectrometryValerie A Frerichs
Pharmacotherapy Research Center, Core Analytical Laboratory, Department of Pharmacy Practice, University at Buffalo, State University of New York, Room 317 Hochstetter Hall, Buffalo, NY 14260 1200, USA
J Chromatogr B Analyt Technol Biomed Life Sci 787:393-403. 2003..The evolution of complex drug interactions assessments and the clinical use of therapeutic drug monitoring for these antiretrovirals will be a potential immediate application of this method... - Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometryRobin DiFrancesco
Department of Pharmacy Practice, University at Buffalo, NY 14260, United States
J Pharm Biomed Anal 44:1139-46. 2007..The method successfully measured LPV concentrations in CSF that were previously undetectable by HPLC as well as UF from protein binding studies... - Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trialRobin DiFrancesco
Department of Pharmacy Practice, SUNY at Buffalo, Buffalo, NY, USA
Ther Drug Monit 32:458-66. 2010..The application of some of these findings may also be relevant to single-center studies or clinical TDM programs within a hospital... - Drug interactions with antiretroviralsLinda M Catanzaro
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, NY 14260, USA
Curr HIV/AIDS Rep 1:89-96. 2004..This review provides an updated summary of key drug interactions that have been reported since its initial publication... - Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairmentSarah M McCabe
Department of Pharmacy Practice and Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY 14260, USA
Clin Pharmacokinet 47:153-72. 2008..This review summarizes the current knowledge of the use of antiretrovirals in patients with hepatic or renal impairment, and makes dosing recommendations for this subpopulation of HIV-infected patients... - Drug interactions between proton pump inhibitors and antiretroviral drugsSarah M McCabe
Associate Dean, Clinical Education and Research, University of Buffalo, Department of Pharmacy Practice, 317 Hochstetter Hall, Buffalo, NY 14260, USA
Expert Opin Drug Metab Toxicol 3:197-207. 2007..This review summarizes the current knowledge on the interactions between proton pump inhibitors and antiretrovirals, and makes recommendations for the coadministration of proton pump inhibitors... - Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjectsRobert Dicenzo
University at Buffalo, Buffalo, New York 14260, USA
Antimicrob Agents Chemother 48:918-23. 2004..5 to 5,540 ng/ml). Due to the unacceptable number of undetectable indinavir trough concentrations, 1200 mg of indinavir appears to be the preferred dose in a twice-daily regimen that includes nelfinavir... - Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaksOlanrewaju Okusanya
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 317 Hochstetter Hall, Amherst, NY 14260, USA
Antimicrob Agents Chemother 51:1822-6. 2007..The nature of the secondary peaks may be an important consideration for the interpretation of amprenavir plasma concentrations during therapeutic drug monitoring... - Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
Pharmacotherapy 26:341-6. 2006..01). CONCLUSION: Acid suppression markedly reduced the bioavailability of atazanavir in this group of healthy volunteers. Based on these results, atazanavir should not be coadministered with lansoprazole or other proton pump inhibitors... - Data from clinical trialsLinda M Catanzaro
Laboratory for Antiviral Research, ACTG Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, New York, USA
J Acquir Immune Defic Syndr 38:S26-9. 2005 - Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpointsRobin DiFrancesco
Department of Pharmacy Practice, University at Buffalo, Buffalo, New York 14260, USA
HIV Clin Trials 7:203-9. 2006..CONCLUSION: The ACTG clinical pharmacology tutorial program improved accuracy of both protocol conduct and data collection for pharmacology objectives... - Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyDavid W Haas
Vanderbilt University School of Medicine, Nashville, TN 37203, USA
J Infect Dis 192:1931-42. 2005..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment... - Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidityMark J Shelton
GlaxoSmithKline, Five Moore Drive, P.O. Box 1398, Research Triangle Park, NC 27709, USA
J Clin Pharmacol 43:171-9. 2003..HIV-infected subjects with gastric hypoacidity significantly malabsorb delavirdine. Delavirdine administration with acidic beverages improves, but dose not normalize, absorption in these subjects... - A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl
Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
J Infect Dis 188:625-34. 2003..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity... - Pharmacokinetic interactions between buprenorphine and antiretroviral medicationsR Douglas Bruce
Yale University AIDS Program, New Haven, CT 06511, USA
Clin Infect Dis 43:S216-23. 2006..Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions... - The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patientsLisa M Demeter
Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
HIV Clin Trials 9:61-72. 2008.... - Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapyC Bradley Hare
Dept of Medicine, University of California, San Francisco, CA 94110, USA
Clin Infect Dis 47:421-4. 2008..Mutations remained detectable for at least 48 weeks in some subjects... - A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavirScott M Hammer
Columbia University, New York, NY, USA
Antivir Ther 8:507-18. 2003 - Interaction between buprenorphine and atazanavir or atazanavir/ritonavirElinore F McCance-Katz
Virginia Commonwealth University, Richmond, VA, USA
Drug Alcohol Depend 91:269-78. 2007..Atazanavir or atazanavir/ritonavir may increase buprenorphine and buprenorphine metabolite concentrations and might require a decreased buprenorphine dose... - Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdineElinore F McCance-Katz
Virginia Commonwealth University, Richmond, Virginia 23298, USA
Am J Addict 15:23-34. 2006.... - Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdineElinore F McCance-Katz
Virginia Commonwealth University, Richmond, USA
Clin Infect Dis 43:S224-34. 2006..Adjustments of doses of either buprenorphine or EFV or DLV are not likely to be necessary when these drugs are administered for the treatment of opiate dependence and HIV disease... - Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavirElinore F McCance-Katz
Virginia Commonwealth University, Richmond, USA
Clin Infect Dis 43:S235-46. 2006..Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease... - Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyAlison A Motsinger
Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
Pharmacogenet Genomics 16:837-45. 2006..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms... - Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavirTroy M Martin
AIDS 20:1085-7. 2006 - Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyCalvin J Cohen
Community Research Initiative of New England, Boston, MA 02215, USA
HIV Clin Trials 8:19-23. 2007.... - Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infectionRobert W Shafer
Stanford University Medical Center, Stanford, Calif, USA
N Engl J Med 349:2304-15. 2003..It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens... - Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoringDiane T Holland
Pediatric Pharmacology Laboratory, University of California, San Diego, USA
Ther Drug Monit 28:367-74. 2006..The percentage of correct results is about the same as previously reported. There is a continued need for a PT program to help participating laboratories maintain essential quality assurance and quality control... - Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratoriesDiane T Holland
Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group, Division of AIDS, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland, USA
Antimicrob Agents Chemother 48:824-31. 2004..In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials... - HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countriesCharles C Maponga
University of Zimbabwe College of Health Science, Avondale, Harare, Zimbabwe
Top HIV Med 15:104-10. 2007..The potential for the effective international collaboration is enhanced when expertise and resources from the developed world are combined with an understanding of the unique priorities of resource-limited settings...
Research Grants
- Antiretroviral Pharmacology Training in Resource Poor CountriesGene Morse; Fiscal Year: 2009....
- TDM & Drug Interactions in HIVinfected Substance AbusersGene Morse; Fiscal Year: 2007..abstract_text> ..
- TDM & Drug Interactions in HIVinfected Substance AbusersGene Morse; Fiscal Year: 2006....